demonstrated that high expression of FOXO3 was relevant with the progression of glioblastoma, suggesting a poor prognosis for patients with glioblastoma (48), the same result for triple-negative breast cancer (49) and hepatocellular carcinoma (50). This evidence concerns the gene FOXO3 and hepatocellular carcinoma.